What is Oxyntomodulin?
Oxyntomodulin (OXM) is a 37-amino-acid endogenous peptide hormone secreted from intestinal L-cells postprandially, alongside GLP-1 and PYY. It is unusual among gut peptides in that it activates two receptors simultaneously:
- The glucagon-like peptide-1 receptor (GLP-1R)
- The glucagon receptor (GCGR)
This dual-receptor pharmacology makes OXM the template molecule from which the entire next-generation GLP-1/glucagon dual-agonist class has been engineered:
- Survodutide (Boehringer Ingelheim, Phase 3)
- Pemvidutide (Altimmune, Phase 3)
- Mazdutide (Innovent/Lilly, NMPA-approved 2025 in China)
- Retatrutide (Lilly, Phase 3, GLP-1/GIP/glucagon triple agonist — extends OXM's design with GIP)
OXM itself is research-only; it is not approved as a therapeutic. Its pharmacology has been studied in early human clinical trials, where it produced meaningful weight loss but had a half-life too short for practical chronic dosing — motivating the engineering of long-acting OXM analogues.
Structure
Oxyntomodulin is encoded by the proglucagon gene (the same gene that gives rise to glucagon, GLP-1, and GLP-2). Tissue-specific processing of proglucagon by prohormone convertases yields different products in different cells:
- Pancreatic α-cells: process proglucagon to glucagon (29 AA)
- Intestinal L-cells: process proglucagon to GLP-1 (7-37), GLP-2, glicentin, and OXM
OXM's sequence is glucagon (residues 1-29) + an 8-residue C-terminal extension (residues 30-37). The N-terminal glucagon sequence is responsible for glucagon receptor activation; both N-terminal and C-terminal portions contribute to GLP-1 receptor binding.
Mechanism of Action
GLP-1 receptor activation:
- Glucose-dependent insulin secretion
- Glucagon suppression
- Slowed gastric emptying
- Central appetite suppression
Glucagon receptor activation:
- Hepatic glycogenolysis and gluconeogenesis
- Hepatic lipolysis
- Increased energy expenditure (thermogenesis)
- Reduced hepatic steatosis (via lipid mobilization)
Net therapeutic effect: weight loss via reduced food intake (GLP-1) plus increased energy expenditure (glucagon), with hepatic steatosis improvement (glucagon-driven lipolysis offset by GLP-1-driven insulin secretion preventing hyperglycemia).
Clinical Evidence
Wynne et al. 2005 (Diabetes):
- Single-blind, placebo-controlled trial of subcutaneous OXM 3 times daily for 4 weeks in overweight subjects
- 2.3 kg weight loss vs 0.5 kg placebo at 4 weeks
- Reduced food intake, increased energy expenditure
- Established OXM's therapeutic potential — but TID injection regimen was impractical
These early data motivated the development of long-acting OXM analogues that could be dosed weekly or monthly.
Place in Research and Drug Discovery
OXM has been the conceptual and structural template for an entire class of obesity therapeutics. The progression from native OXM to clinically successful drugs:
- Native OXM (research, t½ minutes) — proof-of-concept of dual GLP-1/GCGR mechanism
- First-generation OXM analogues (research, t½ hours) — backbone modifications, DPP-4 resistance
- Second-generation OXM analogues (clinical) — fatty-acid acylation for albumin binding, weekly dosing — survodutide, pemvidutide, mazdutide
- Triple agonist (clinical) — adding GIP receptor activation — retatrutide
The receptor-balance ratio in each engineered analogue tunes the therapeutic profile:
- GLP-1 dominant (survodutide, mazdutide) — strong weight loss with milder metabolic effects
- Balanced 1:1 (pemvidutide) — strong hepatic effects for MASH, balanced weight loss
Place in Research
OXM remains an active research peptide for:
- Receptor pharmacology of dual agonists
- Mechanism studies of GLP-1 vs GCGR contributions to weight loss
- Energy expenditure research
- Hepatic steatosis and MASH model development
It is sold by research chemical suppliers and used widely in preclinical studies of dual-agonist mechanism.
Note for Researchers
OXM's 4-minute half-life in vivo limits its utility for chronic dosing studies. Researchers studying chronic dual-agonist effects typically use the long-acting analogues (survodutide, pemvidutide, etc.) rather than native OXM. Native OXM is more relevant for acute receptor pharmacology and proof-of-concept experiments.